Fund shareholders of Apellis Pharmaceuticals Inc
ISIN US03753U1060 · United States · LEI 254900HS0ZFRXXSB9D42
- Fund shareholders
- 2
- Of which ETFs
- 0 2 other funds
- Value held
- ≈ 1.8M $ 320.7K € · 13.6M SEK
- Share of capital
- 0.0 % of 128M shares on Apr 21, 2026
2 tracked funds declare this company. So these figures do not say who owns it.
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Handelsbanken Global Småbolag Index Criteria Handelsbanken Fonder AB | 35,400 | 13.6M SEK | 0.05 % | 0.03 % | as of Mar 31, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 320.7K € | 0.39 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 0.39 % | as of Dec 31, 2025 ↗ |
| Handelsbanken Global Småbolag Index Criteria Handelsbanken Fonder AB | 0.05 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 222 | +41 | 33,782,707 | +6.8 % |
| 2026Q1 | 181 | -10 | 31,643,925 | -2.7 % |
| 2025Q4 | 191 | +15 | 32,520,512 | +14.4 % |
| 2025Q3 | 176 | -27 | 28,418,186 | -14.6 % |
| 2025Q2 | 203 | -8 | 33,263,574 | -2.6 % |
| 2025Q1 | 211 | -45 | 34,151,298 | -19.0 % |
| 2024Q4 | 256 | -25 | 42,187,393 | -9.7 % |
| 2024Q3 | 281 | -22 | 46,717,562 | +5.2 % |
| 2024Q2 | 303 | +4 | 44,404,342 | +24.2 % |
| 2024Q1 | 299 | +15 | 35,757,319 | -19.7 % |
| 2023Q4 | 284 | 44,540,602 |
Institutional managers
311 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| BlackRock, Inc. | 13,536,964 | 544.6M $ | as of Mar 31, 2026 |
| Avoro Capital Advisors LLC | 12,222,222 | 491.7M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 10,042,399 | 404M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 6,844,990 | 275.4M $ | as of Mar 31, 2026 |
| UBS Group AG | 6,206,681 | 249.7M $ | as of Mar 31, 2026 |
| Pentwater Capital Management LP | 5,250,000 | 211.2M $ | as of Mar 31, 2026 |
| Deep Track Capital, LP | 4,532,374 | 182.3M $ | as of Mar 31, 2026 |
| Point72 Asset Management, L.P. | 4,183,918 | 168.3M $ | as of Mar 31, 2026 |
| RTW INVESTMENTS, LP | 3,685,045 | 148.2M $ | as of Mar 31, 2026 |
| HBK INVESTMENTS L P | 3,550,000 | 142.8M $ | as of Mar 31, 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,518,471 | 141.5M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 2,256,802 | 90.8M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,075,075 | 83.5M $ | as of Mar 31, 2026 |
| JPMORGAN CHASE & CO | 2,047,927 | 35M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 1,980,144 | 79.7M $ | as of Mar 31, 2026 |
| Balyasny Asset Management L.P. | 1,917,501 | 77.1M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 1,338,995 | 53.7M $ | as of Mar 31, 2026 |
| GLAZER CAPITAL, LLC | 1,294,196 | 52.1K $ | as of Mar 31, 2026 |
| TIG Advisors, LLC | 1,252,986 | 50.4M $ | as of Mar 31, 2026 |
| TORONTO DOMINION BANK | 1,236,436 | 49.7M $ | as of Mar 31, 2026 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1,202,100 | 48.4M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 1,190,864 | 47.9M $ | as of Mar 31, 2026 |
| Hudson Bay Capital Management LP | 1,190,416 | 47.9M $ | as of Mar 31, 2026 |
| FIL Ltd | 1,140,000 | 45.9M $ | as of Mar 31, 2026 |
| Kryger Capital LLC | 1,100,000 | 44.3M $ | as of Mar 31, 2026 |
Cite this page
Titelia. "Fund shareholders of Apellis Pharmaceuticals Inc". https://titelia.com/en/stocks/apellis-pharmaceuticals-inc-US03753U1060